This MedLibrary.org supplementary page on Biota Holdings is provided directly from the open source Wikipedia as a service to our readers. Please see the note below on authorship of this content, as well as the Wikipedia usage guidelines. To search for other content from our encyclopedia supplement, please use the form below:
Related Sponsors
Biota is an Australian antiviral drug development company listed on the Australian Stock Exchange (ASX:BTA).
In 1989 Biota discovered the drug Zanamivir, which acts as a neuraminidase inhibitor for the treatment and prevention of influenza. This drug is licensed to GlaxoSmithKline and marketed as Relenza. Zanamivir is currently being stockpiled by governments around the world in the wake of a possible avian influenza pandemic.
External links
 This article about an Australian corporation or company is a stub. You can help Wikipedia by expanding it. |
|
This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by expanding it. |
Wikipedia content modification information:
- This page was last modified on 5 June 2008, at 10:00.
Wikipedia Authorship and Review
Wikipedia content provided here is not reviewed directly by MedLibrary.org. Wikipedia content is authored by an open community of volunteers and is not produced by or in any way affiliated with MedLibrary.org.
Wikipedia Usage Guidelines
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article on "Biota Holdings".
The URL for this specific entry is:
All Wikipedia text is available under the terms of the GNU Free Documentation License. (See Copyrights for details). Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc.